MTOR

mechanistic target of rapamycin (serine/threonine kinase)
back to Gene Panel Summary
 
Known Variants (dbSNP)
Harmful Beneficial Normal
2 - 71
Novel Variants
Harmful Beneficial Normal
- - -
Variants by Type Count
Insertions & Deletions 4
Known Variants (dbSNP) 73
With Severity Score 7
Total 73

Known vs. Novel Variants
Known Variants
73
Novel
0

Functional Consequence of Variants
Known Variants
Novel Variants
Known Variants Novel Variants
Harmful, Score > 3
2
0
Beneficial
0
0
Normal, Score 0-2
71
0

Gene Details  

The protein encoded by this gene belongs to a family of phosphatidylinositol kinase-related kinases. These kinases mediate cellular responses to stresses such as DNA damage and nutrient deprivation. This protein acts as the target for the cell-cycle arrest and immunosuppressive effects of the FKBP12-rapamycin complex. The ANGPTL7 gene is located in an intron of this gene.

research MTOR on OMIM...
Pharmaceuticals  
FDA approved drugs to treat condition Click on drug names to see more info
Temserolimus

Temsirolimus (CCI-779) is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the U.S. Food and Drug Administration (FDA) in late May 2007,[1] and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative of sirolimus and is sold as Torisel.

Everolimus

Everolimus (RAD-001) is the 40-O-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an mTOR (mammalian target of rapamycin) inhibitor.
It is currently used as an immunosuppressant to prevent rejection of organ transplants. Much research has also been conducted on everolimus and other mTOR inhibitors for use in a number of cancers.
It is marketed by Novartis under the tradenames Zortress (USA) and Certican (Europe and other countries) in transplantation medicine, and Afinitor in oncology.

Drugs in clinical trials
Ridaforolimus several PI3K / mTOR dual inhibitors

www.ionflux.com